Cargando…
The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL
Following a multivariant analysis we demonstrated that children and adolescents with Burkitt lymphoma (BL) and a 13q14.3 deletion have a significant decrease in event free survival (EFS) despite identical short intensive multi-agent chemotherapy. However, how this deletion in the 13q14.3 region is a...
Autores principales: | Lee, Sanghoon, Luo, Wen, Shah, Tishi, Yin, Changhong, O’Connell, Timmy, Chung, Tae-Hoon, Perkins, Sherrie L, Miles, Rodney R, Ayello, Janet, Morris, Erin, Harrison, Lauren, van de Ven, Carmella, Cairo, Mitchell S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438612/ https://www.ncbi.nlm.nih.gov/pubmed/28427156 http://dx.doi.org/10.18632/oncotarget.15711 |
Ejemplares similares
-
Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model
por: Lee, Sanghoon, et al.
Publicado: (2018) -
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment
por: Awasthi, Aradhana, et al.
Publicado: (2017) -
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL
por: Chu, Yaya, et al.
Publicado: (2020) -
PB2135: BURKITT LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (BL-IPI): IS IT EFFICIENT ENOUGH IN ADULT BURKITT LYMPHOMA PATIENTS?
por: Sayinalp, B., et al.
Publicado: (2022) -
Immunophenotypic, cytotoxic, proteomic and genomic characterization
of human cord blood vs. peripheral blood CD56(Dim) NK
cells
por: Shereck, Evan, et al.
Publicado: (2019)